Leukemia
Acute Myeloid Leukemia: Public Health and Genomics - August 28, 2015
Molecular genetic markers in acute myeloid leukemia.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Yohe S et al. J Clin Med 2015 (3) 460-78
Yohe S et al. J Clin Med 2015 (3) 460-78
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Lavallée VP et al. Nat. Genet. 2015 Sep (9) 1030-1037
Lavallée VP et al. Nat. Genet. 2015 Sep (9) 1030-1037
Toward individualized therapy in acute myeloid leukemia: A contemporary review.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Kadia TM et al. JAMA Oncol 2015 Apr 30.
Kadia TM et al. JAMA Oncol 2015 Apr 30.
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Gallipoli P et al. Ther Adv Hematol 2015 Jun (3) 103-19
Gallipoli P et al. Ther Adv Hematol 2015 Jun (3) 103-19
Why is progress in acute myeloid leukemia so slow?![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Estey E et al. Semin. Hematol. 2015 Jul (3) 243-8
Estey E et al. Semin. Hematol. 2015 Jul (3) 243-8
Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia: ready for clinical practice?![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Pastore F et al. JAMA 2015 Aug 25. 314(8) 778-780
Pastore F et al. JAMA 2015 Aug 25. 314(8) 778-780
The limits of FDA's authority to regulate clinical research involving high-throughput DNA sequencing.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Evans BJ et al. Food Drug Law J 2015 70(2) 259-87, ii
Evans BJ et al. Food Drug Law J 2015 70(2) 259-87, ii
Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Klco JM et al. JAMA 2015 Aug 25. 314(8) 811-822
Klco JM et al. JAMA 2015 Aug 25. 314(8) 811-822
Acute Lymphoblastic Leukemia: Pharmacogenomic Insights - June 1, 2015
The pharmacogenomics of Vincristine-induced neuropathy: On pins and needles![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Berg SL et al. JAMA Oncology, May 29, 2015
Berg SL et al. JAMA Oncology, May 29, 2015
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Mei L et al. Blood Rev. 2015 Jan 10.
Mei L et al. Blood Rev. 2015 Jan 10.
Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Pui Ching-Hon et al. Front Med 2015 Mar (1) 1-9
Pui Ching-Hon et al. Front Med 2015 Mar (1) 1-9
Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Lennard L et al. Br. J. Haematol. 2015 Apr (2) 228-40
Lennard L et al. Br. J. Haematol. 2015 Apr (2) 228-40
Pharmacogenetics of childhood acute lymphoblastic leukemia.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Lopez-Lopez E et al. Pharmacogenomics 2014 Jul (10) 1383-98
Lopez-Lopez E et al. Pharmacogenomics 2014 Jul (10) 1383-98
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Hoang Phuong TV et al. Br J Clin Pharmacol 2015 Mar (3) 429-40
Hoang Phuong TV et al. Br J Clin Pharmacol 2015 Mar (3) 429-40
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Dulucq S et al. Expert Opin Drug Metab Toxicol 2014 May (5) 699-719
Dulucq S et al. Expert Opin Drug Metab Toxicol 2014 May (5) 699-719
Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
López-López E et al. PLoS ONE 2014 (3) e91261
López-López E et al. PLoS ONE 2014 (3) e91261
Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tDi6j3k1p9CW3fwK58dJOPh4DhoUIQdEpD6QLKRpbGfeyOoCdYuNJ4Q3hIkmLykwG84cPR6CyxqinRxLL1zVRDPslVF8hxbk6iIx_2XaNoKxQ_Hl9wC8zI=s0-d)
Kodidela S et al. Eur. J. Clin. Pharmacol. 2014 Mar (3) 253-60
Kodidela S et al. Eur. J. Clin. Pharmacol. 2014 Mar (3) 253-60
Pharmacogenetics of childhood acute lymphoblastic leukemia,
by E Lopez-Lopez et al, Medscape, 2014
No hay comentarios:
Publicar un comentario